Harmony Biosciences Holdings, Inc. HRMY Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 76.5%-1.8pp | 77.2%-0.9pp | 77.7%-1.0pp | 78.3%-1.1pp | 78.3%-0.9pp | |
| Operating margin | 21.1%-5.1pp | 24%-2.7pp | 27.3%+1.6pp | 28.7%+1.6pp | 26.2%-6.8pp | |
| Net margin | 16.2%-4.3pp | 18.3%-2.1pp | 22.5%+4.5pp | 23.4%+5.9pp | 20.5%-1.8pp | |
| Returns | ||||||
| Return on equity | 17.9%-6.9pp | 20.8%-5.1pp | 25.9%+3.2pp | 27.6%+5.1pp | 24.7%-4.0pp | |
| Return on invested capital | 31.2%-7.3pp | 45.6%+6.4pp | 48.3%+15.7pp | 44%+11.8pp | 38.5%-2.8pp | |
| Efficiency | ||||||
| Asset turnover | 0.8×0.0× | 0.8×0.0× | 0.8×0.0× | 0.8×0.0× | 0.8×0.0× | |
| Liquidity | ||||||
| Current ratio | 3.6×-0.1× | 3.6×+0.3× | 3.8×+0.5× | 3.8×+0.7× | 3.7×+0.6× | |
| Leverage | ||||||
| Debt-to-equity | 0.2×-0.1× | 0.2×-0.1× | 0.2×-0.1× | 0.2×-0.1× | 0.2×-0.1× | |
| Net debt / EBITDA | -2×-0.6× | -2.5×-1.2× | -1.9×-0.9× | -1.5×-0.9× | -1.4×-0.8× | |
| Per Share | ||||||
| Book value per share | $15.49+25.8% | $14.86+30.5% | $14.22+38.5% | $13.23+41.4% | $12.31+37.6% | |
| Valuation | ||||||
| Market capitalization | $1.62B-14.9% | $2.16B+9.8% | $1.59B-30.2% | $1.84B+7.5% | $1.9B-0.2% | |
| Price / earnings | 11.1×-1.3× | 13.6×+0.1× | 8.5×-10.0× | 10.2×-4.7× | 12.5×-1.4× | |
| Price / sales | 1.8×-0.8× | 2.5×-0.3× | 1.9×-1.4× | 2.4×-0.2× | 2.6×-0.5× | |
| Price / book | 1.8×-0.9× | 2.5×-0.5× | 1.9×-1.9× | 2.4×-0.8× | 2.6×-1.1× | |
| EV / EBITDA | 5.6×-1.7× | 6.8×-1.1× | 4.4×-5.9× | 6×-1.8× | 7.3×-0.5× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Harmony Biosciences Holdings, Inc.'s profit margins?
- Harmony Biosciences Holdings, Inc. (HRMY) runs a 76.5% gross margin and a 21.1% operating margin, with a 16.2% net margin.
- Where do Harmony Biosciences Holdings, Inc.'s ratios come from?
- Every ratio is computed from Harmony Biosciences Holdings, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
